We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Secukinumab 300 mg administered with an auto-injector ...

Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti–interleukin-17A monoclonal antibody, in patients with moderate-to-severe ...

Secukinumab achieved complete symptom resolution in patients with pediatric generalized pustular psoriasis (GPP) by week 2, with sustained improvements through week 70. The treatment regimen was ...

Secukinumab is an anti–interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in ...